news

CUPERTINO, Calif., March 1 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today the appointment of Armand P. Neukermans Ph.D. to its Board of Directors. Dr. Neukermans is currently Chief Technical Officer of the Xros division at Nortel Networks. Dr. Neukermans has over 30 years of experience in the field of electrical and mechanical engineering. Since […]

CUPERTINO, Calif., March 1 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present a company overview and discuss the Phase II trial in progress for its lead product, DUROS sufentanil for the treatment of chronic pain, at the 1st Annual Salomon Smith Barney Specialty Pharmaceuticals Conference to be held March 9, 2001

CUPERTINO, Calif., Feb. 16 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2000 and reports strong progress in the company’s business operations. The company reiterated its accelerated progress in the Phase II clinical trials for DUROS sufentanil and announced that it expects to complete

CUPERTINO, Calif., Feb. 15 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months and year ended December 31, 2000. The Company’s net loss attributable to common stockholders for the three months ended December 31, 2000 was $4.9 million or 11 cents per share, compared to a net loss of $3.6

CUPERTINO, Calif., Feb. 7 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that the company expects to complete enrollment of its 50 patient Phase II clinical trial for the company’s lead product, DUROS sufentanil, ahead of the previously anticipated date for completion of enrollment. DUROS sufentanil is designed to deliver sufentanil on a continuous basis

CUPERTINO, Calif., Jan. 24 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that Evelyn R. Robledo has been promoted to Vice President of Quality Assurance and Compliance. Ms. Robledo joined DURECT in March 2000 and, utilizing her solid understanding of FDA regulations, developed and implemented an effective Quality Assurance System to support DURECT’s product development

CUPERTINO, Calif., Jan. 22 /PRNewswire/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) fourth quarter financial results press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Thursday, February 15, 2001 at 4:30 p.m. EST with Jim Brown, President and Chief Executive Officer, Tom Schreck,

CUPERTINO, Calif., Dec. 12 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it will present a company overview and discuss the Phase II trial in progress for its lead product, DUROS sufentanil for the treatment of chronic pain, at the 19th Annual Healthcare Conference to be held January 9, 2001 at 2:00 P.M. in

CUPERTINO, Calif., Dec. 11 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced enrollment of the patients into a Phase II clinical trial for the company’s lead product, DUROS sufentanil, for the treatment of chronic pain. DUROS sufentanil uses the DUROS osmotic delivery system to deliver sufentanil on a continuous basis for 3 months. Sufentanil is

CUPERTINO, Calif., Nov. 13 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2000. DURECT’s net loss attributable to common stockholders for its third quarter ended September 30, 2000 was $6.0 million dollars, or $0.62 cents per diluted share, compared to a net loss of $2.4 million